Transgene

Transgene Earnings Yield

The Earnings Yield of Transgene (TNG.PA) as of Nov 18, 2026 is -14.59 %. In the previous year, Earnings Yield was -9.59 % — a change of 52.15% (lower).

Earnings Yield

-14.59 %

YoY

52.15%

Last updated:

Earnings Yield of Transgene is 2024 -14.59 % . Earnings Yield of Transgene was 2023 -9.59 % . It decreases by 52.15% lower compared to the previous year.

The Transgene Earnings Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Earnings Yield
Date
Earnings Yield
Jan 1, 2017
-13.86 EUR
Jan 1, 2018
3.45 EUR
Jan 1, 2019
-8.08 EUR
Jan 1, 2020
-7.40 EUR
Jan 1, 2021
-8.39 EUR
Jan 1, 2022
-14.09 EUR
Jan 1, 2023
-9.59 EUR
Jan 1, 2024
-14.59 EUR
The Transgene Earnings Yield history
YEAREarnings YieldYoY
-14.59 %+52.15%
-9.59 %-31.94%
-14.09 %+67.92%
-8.39 %+13.38%
-7.40 %-8.37%
-8.08 %-334.29%
3.45 %-124.87%
-13.86 %+28.04%
-10.83 %-45.64%
-19.92 %-4.49%
-20.86 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Earnings Yield of Transgene is -14.59 % in 2024.

Earnings Yield of Transgene changed from -9.59 % to -14.59 %, representing a 52.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings Yield Transgene since 2006 – with annual values, charts, and detailed analysis.

Earnings Yield is the inverse of the P/E ratio. It shows the percentage of each dollar invested that was earned by the company. Higher earnings yield indicates better value.

To evaluate Earnings Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Earnings Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Earnings Yield's Transgene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Transgene

All Key Metrics — Transgene